Plasma p-tau217 detects Alzheimer's disease co-pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort.

Cerebral amyloid angiopathy (CAA) frequently co-occurs with Alzheimer's disease (AD), generating mixed vascular-neurodegenerative phenotypes. Plasma phosphorylated tau (p-tau)217 is a robust biomarker of AD, but its performance in CAA remains unclear.

We studied 231 participants, including 50 patients with CAA (Boston v2.0), 154 with AD, and 27 cognitively unimpaired controls. Plasma p-tau217 was measured on an automated platform and compared to cerebrospinal fluid (CSF)-defined AD status. Associations with magnetic resonance imaging (MRI) markers of CAA burden were evaluated.

Among CAA participants, 29 met CSF criteria for AD co-pathology. Plasma p-tau217 discriminated CAA patients with and without AD co-pathology (area under the curve = 0.920) and showed no association with MRI markers of CAA burden. Predefined cut-offs (≥ 0.27 pg/mL and ≥ 0.34 pg/mL) yielded high accuracy for identifying AD co-pathology within CAA.

Plasma p-tau217 shows high diagnostic accuracy for identifying AD co-pathology in CAA and is not associated with MRI markers of CAA burden, supporting its specificity for AD-related pathology.
Cardiovascular diseases
Access
Advocacy

Authors

Fernández-Lebrero Fernández-Lebrero, Jiménez-Balado Jiménez-Balado, García-Escobar García-Escobar, Contador Contador, Estraguès-Gázquez Estraguès-Gázquez, Peraferrer-Montesinos Peraferrer-Montesinos, Manero-Borràs Manero-Borràs, Gramegna Gramegna, Viles Viles, Campello Campello, Ortiz-Romero Ortiz-Romero, de Diego de Diego, Del Campo Del Campo, Torres-Torronteras Torres-Torronteras, Jiménez-Moyano Jiménez-Moyano, Blasco-Forniés Blasco-Forniés, Suárez-Calvet Suárez-Calvet, Ois Ois, Puig-Pijoan Puig-Pijoan, Navalpotro-Gómez Navalpotro-Gómez
View on Pubmed
Share
Facebook
X (Twitter)
Bluesky
Linkedin
Copy to clipboard